The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy.
Using a simple method for the selection of hybrid cell growth from the cell fusion of pairs of existing hybridoma cell lines, 2 different hybrid-hybridoma cell lines were produced. Both hybrid-hybridomas secreted bi-specific antibody with similar specificity for human CD3 and for mouse Thy-l but in...
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Journal article |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
1988
|
| _version_ | 1826306805199798272 |
|---|---|
| author | Clark, M Gilliland, L Waldmann, H |
| author_facet | Clark, M Gilliland, L Waldmann, H |
| author_sort | Clark, M |
| collection | OXFORD |
| description | Using a simple method for the selection of hybrid cell growth from the cell fusion of pairs of existing hybridoma cell lines, 2 different hybrid-hybridoma cell lines were produced. Both hybrid-hybridomas secreted bi-specific antibody with similar specificity for human CD3 and for mouse Thy-l but in one case the parental antibody isotypes were both IgG2b and in the other case the CD3 antibody was IgG2b and the anti-Thy-l antibody was IgG2c. In a model in vitro system both bi-specific antibodies were able to elicit potent cell killing of a Thy-l expressing mouse tumour cell line by human effector cell blasts. The cell blasts were generated from resting peripheral blood mononuclear cells using a mitogenic monoclonal antibody (MAb) (YTH361). The parental anti-Thy-l IgG2b but not the IgG2c antibody was also able to mediate cell killing by ADCC. This ADCC killing was inhibited by a MAb to the CD16 Fc receptor but the killing elicited by the bi-specific antibodies was not. Both mechanisms of tumour cell killing may be of great potential in human tumour therapy with MAbs. |
| first_indexed | 2024-03-07T06:53:28Z |
| format | Journal article |
| id | oxford-uuid:fd51337a-a9be-4b92-a55c-4540e4329692 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:53:28Z |
| publishDate | 1988 |
| record_format | dspace |
| spelling | oxford-uuid:fd51337a-a9be-4b92-a55c-4540e43296922022-03-27T13:27:59ZThe potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fd51337a-a9be-4b92-a55c-4540e4329692EnglishSymplectic Elements at Oxford1988Clark, MGilliland, LWaldmann, HUsing a simple method for the selection of hybrid cell growth from the cell fusion of pairs of existing hybridoma cell lines, 2 different hybrid-hybridoma cell lines were produced. Both hybrid-hybridomas secreted bi-specific antibody with similar specificity for human CD3 and for mouse Thy-l but in one case the parental antibody isotypes were both IgG2b and in the other case the CD3 antibody was IgG2b and the anti-Thy-l antibody was IgG2c. In a model in vitro system both bi-specific antibodies were able to elicit potent cell killing of a Thy-l expressing mouse tumour cell line by human effector cell blasts. The cell blasts were generated from resting peripheral blood mononuclear cells using a mitogenic monoclonal antibody (MAb) (YTH361). The parental anti-Thy-l IgG2b but not the IgG2c antibody was also able to mediate cell killing by ADCC. This ADCC killing was inhibited by a MAb to the CD16 Fc receptor but the killing elicited by the bi-specific antibodies was not. Both mechanisms of tumour cell killing may be of great potential in human tumour therapy with MAbs. |
| spellingShingle | Clark, M Gilliland, L Waldmann, H The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title_full | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title_fullStr | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title_full_unstemmed | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title_short | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. |
| title_sort | potential of hybrid antibodies secreted by hybrid hybridomas in tumour therapy |
| work_keys_str_mv | AT clarkm thepotentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy AT gillilandl thepotentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy AT waldmannh thepotentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy AT clarkm potentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy AT gillilandl potentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy AT waldmannh potentialofhybridantibodiessecretedbyhybridhybridomasintumourtherapy |